Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

GILD

$170.683.06%5.07

Dopo l'orario di chiusura: 170.73+0.05 +0.03%

Gilead Sciences Inc (GILD)

Date: O: H: L: C: Vol:

Gilead Sciences Inc Borsa (GILD) Ultime notizie

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth - Zacks Investment Research

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks - Zacks Investment Research

Gilead Sciences (GILD) Reports Strong Q3 2026 Sales Growth, Rais - GuruFocus

Gilead Sciences Inc (GILD) (Q3 2026) Earnings Call Highlights: Base Business Surges 16% as HIV ... - Yahoo Finance

What Gilead Sciences (GILD) Said on Its Q3 Earnings Call - Yahoo Finance

Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Zacks Investment Research

Gilead Sciences, Inc. (GIS.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Gilead Sciences, Inc. (GILD.VI) Seasonal returns chart - Yahoo Finance Australia

Gilead Sciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:GILD) 2026-10-29 - Seeking Alpha

Gilead Sciences, Inc. (GILD) Seasonal returns chart - Yahoo Finance UK

Gilead Sciences, Inc. (GILD.MX) Seasonal returns chart - Yahoo Finance Australia

Gilead Sciences, Inc. (GILD) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Gilead Sciences, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView

Gilead Sciences Q3 2026 Earnings Call Transcript - Benzinga

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade - Investor's Business Daily

A Look at Gilead Sciences Inc (GILD) After 4.0% Gain -- GF Value $107.30 vs Price $165.61 - GuruFocus

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength - WSJ

Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations - Yahoo Finance

Gilead: Q3 Earnings Snapshot - Yahoo Finance

Gilead hikes full-year sales outlook, quarterly HIV sales rise 18% - Yahoo Finance

Breakfast News: Brace for an AI Optics Shake-up - The Motley Fool

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial - GlobeNewswire Inc.

Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research

Gilead Sciences earnings: what to look for from GILD - Yahoo Finance

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Gilead to Report Q3 Earnings: How Should You Play the Stock Now? - Zacks Investment Research

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research

Gilead Sciences, Inc. (GIS.F) Stock Price, News, Quote & History - Yahoo! Finance Canada

Is Gilead Stock Increasing Your Market Risk? - Trefis

What Would A Biktarvy Slowdown Do To Gilead Stock? - Trefis

Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet

BHC Q3 Earnings Preview: Here's What You Should Know - Zacks Investment Research

Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet

Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? - Benzinga

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool

TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake - MarketBeat

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - Yahoo Finance

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - The Motley Fool

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool

Gilead expands in I&I with $1.28B Pepstar deal for oral IL-23Ri - BioWorld News

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche - Pharmaceutical Executive

Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar - BioSpace

Simile a GILD

AMGN$466.011.15%

AZN$186.657.02%

NVS$160.790.19%